Study Registration Sample Clauses

Study Registration. Sponsor will register the Study with the public clinical trials registry xxx.xxxxxxxxxxxxxx.xxx in accordance with Applicable Laws and Requirements and ICMJE guidelines prior to the enrolment of the first Subject. Where Institution and Principal Investigator wish to use a publicly-accessible website on a voluntary basis (e.g., a university/hospital website) the information related to the Protocol must not exceed the information Sponsor has already posted and it should be sufficient to provide a hyperlink to the trial when registered on xxxx://xxx.xxxxxxxxxxxxxx.xxx/ 9.3 Registrace Studie: Před zařazením prvního Subjektu Zadavatel zaregistruje Studii ve veřejném registru klinických hodnocení xxx.xxxxxxxxxxxxxx.xxx v souladu s Platnými právními předpisy a požadavky a pokyny ICMJE. Bude-li si Zdravotnické zařízení a Hlavní zkoušející přát dobrovolně využít veřejně dostupné webové stránky (např. webové stránky univerzity / nemocnice), nesmí informace týkající se Protokolu přesahovat informace, které Zadavatel již zveřejnil, a po zaregistrování na stránkách xxxx://xxx.xxxxxxxxxxxxxx.xxx by mělo být postačující uvést hypertextový odkaz na tyto stránky.
Sample 1Sample 2
AutoNDA by SimpleDocs
Study Registration. Pfizer encourages Institution and Principal Investigator to register the Study and any synopsis of Study Results on xxx.XxxxxxxxXxxxxx.xxx or such other website as required under Applicable Law before enrollment of the first Study subject or before commencement of data collection.
Sample 1Sample 2
Study Registration. Abbott shall register Studies at either xxx.xxxxxxxxxxxxxx.xxx or any other registry as applicable or required by law and consistent with the guidelines of the International Committee of Medical Journal Editors (“ICMJE”) on trial registrations. 4.5 Registrace studie. Společnost Abbott zaregistruje Studie na stránkách xxx.xxxxxxxxxxxxxx.xxx nebo v jakémkoli jiném registru, který je použitelný nebo vyžadován zákonem a který je v souladu s pokyny Mezinárodního výboru editorů lékařských časopisů (International Committee of Medical Journal Editors, ICMJE) o registraci klinických hodnocení.
Sample 1
Study Registration. RedHill agrees to register the Study at either xxx.xxxxxxxxxxxxxx.xxx or any other registry as applicable or required by law and consistent with the guidelines of the International Committee of Medical Journal Editors on trial registrations.
Sample 1
Study Registration. The Principal Investigator (PI) will register the study on CTRI and the registration number would be provided to them once available.
Sample 1
Study Registration. Pfizer encourages Institution to register the Study and post a synopsis of Study Results on xxx.XxxxxxxxXxxxxx.xxx or other website as required by Applicable Law. 3. INVESTIGATOR-SPONSORED RESEARCH SUPPORT 3.1. ISR Support. Pfizer will provide funding in support of the Study up to a maximum amount of CZK [XXXX], in accordance with the schedule set forth in Attachment A (“ISR Support”). Pfizer will provide the ISR Support only to Institution. Institution is responsible for appropriate dispersal of funds to Participating Sites. Pfizer will not provide the Pfizer Product that is the focus of this non-interventional Study. Study subjects received the Pfizer Product by prescription as part of their standard medical care. 3.2.
Sample 1

Related to Study Registration

  • Domain Name Registration If Customer submits a Service Order(s) for domain name registration services, the following terms shall also apply:

  • No Registration Each Lender agrees that, without the prior written consent of the Borrower and the Administrative Agent, it will not make any assignment hereunder in any manner or under any circumstances that would require registration or qualification of, or filings in respect of, any Loan or Note under the Securities Act or any other securities laws of the United States of America or of any other jurisdiction.

  • Expenses of Registration All expenses incurred in connection with registrations, filings or qualifications pursuant to Sections 2 and 3, including, without limitation, all registration, listing and qualifications fees, printers, legal and accounting fees shall be paid by the Company.

  • Registration (a) No later than the Filing Date, the Company shall file with the Commission the Initial Registration Statement relating to the resale by the Holders of all (or such other number as the Commission will permit) of the Registrable Securities. If Form S-3 is not available for the registration of the resale of Registrable Securities hereunder, the Company shall (i) register the resale of the Registrable Securities on another appropriate form and (ii) undertake to register the Registrable Securities on Form S-3 as soon as such form is available; provided that the Company shall maintain the effectiveness of the Registration Statement then in effect until such time as a Registration Statement on Form S-3 covering the Registrable Securities has been declared effective by the Commission. Subject to the terms of this Agreement, the Company shall use its best efforts to cause a Registration Statement filed under this Agreement (including, without limitation, under Section 3(c)) to be declared effective under the Securities Act within forty-five (45) days after the filing thereof, but in any event no later than the applicable Effectiveness Date, and shall use its best efforts to keep such Registration Statement continuously effective under the Securities Act until all Registrable Securities covered by such Registration Statement (i) have been sold, thereunder or pursuant to Rule 144, or (ii) may be sold without volume or manner-of-sale restrictions pursuant to Rule 144 and without the requirement for the Company to be in compliance with the current public information requirement under Rule 144, as determined by the counsel to the Company pursuant to a written opinion letter to such effect, addressed and acceptable to the Transfer Agent and the affected Holder (the “Effectiveness Period”). The Company shall telephonically request effectiveness of a Registration Statement as of 5:00 p.m. Eastern Time on a Trading Day. The Company shall immediately notify the Holder via facsimile or by e-mail of the effectiveness of a Registration Statement on the same Trading Day that the Company telephonically confirms effectiveness with the Commission, which shall be the date requested for effectiveness of such Registration Statement. The Company shall, by 9:30 a.m. Eastern Time on the Trading Day after the effective date of such Registration Statement, file a final Prospectus with the Commission as required by Rule 424. Failure to so notify the Holders within one (1) Trading Day of such notification of effectiveness or failure to file a final Prospectus as foresaid shall be deemed an Event under Section 2(g).

Time is Money Join Law Insider Premium to draft better contracts faster.